

Patient Demographic Information

Last Name:		First Name:	
Address:		Apt #:	
City:	State:	Zip:	
Primary Phone:		Alt Ph or Email:	
Height:	Weight (kg):	Sex: Male Female	DOB:
Emergency Contact:		Phone:	

Insurance Information

Primary Insurance Provider:	Policy Number:
Phone Number:	Group:
Secondary Insurance Provider:	Policy Number:
Phone Number:	Group:
Employer Name:	Phone Number:

Diagnosis/General Information

Allergies: _____ Pertinent Clinical History: _____ Patient Status (select one): New to therapy Continuation of therapy and last infusion day: _____ Please include the below information in the referral: Demographics Insurance Information Prescription/Order Clinicals showing infusion need: progress notes and diagnostics (i.e. biopsies, labs, tried and failed medication HX, etc.) Labs Additional Information: _____	Patient Diagnosis, ICD-10 Codes: I77.6 Vasculitis unspecified M05 Rheumatoid arthritis with rheumatoid factor M05.79 Rheumatoid arthritis with rheumatoid factor of multiple sites without organ or systems involvement M06.1 Still's disease M30.3 Kawasaki disease M31.30 ANCA-associated vasculitis M32.9 Systemic lupus erythematosus (SLE) M33.00 – M33.99 Dermatomyositis M33.00 Juvenile dermatomyositis M33.20 – M33.29 Polymyositis M35.0 Sjogren syndrome with systemic involvement M45 Ankylosing spondylitis L40.5 Arthropathic psoriasis Other: _____
---	---

Prescription Information

Immunoglobulin (IVIG or SQIG)	_____ gm/kg over _____ days every _____ weeks	IVIG	SQIG
Remicade or other Infliximab product: Remicade, Avsola, Inflectra, Renflexis, Unbranded Infliximab	_____ mg/kg IV or _____ mg at week 0, 2, 6, then every _____ weeks		
Tremfya	Plaque Psoriasis: Inject Tremfya 100mg SQ at week 0, 4, and every 8 weeks thereafter Psoriatic Arthritis: Inject Tremfya 100mg SQ at week 0, 4, and every 8 weeks thereafter		
Actemra or Biosimilar product: Actemra, Tynne	_____ mg/kg IV or _____ mg every _____ weeks		
Cimzia	Induction: 400 mg subcutaneously (2 SQ injections of 200 mg) at weeks 0, 2, and 4 Maintenance dose: _____ mg SQ every _____ weeks		
Rituxan or other Biosimilar product: Rituxan, Ruxience, Truxima, Riabni	Rheumatoid Arthritis: 1000 mg IV at week 0 and week 2, then repeat the 2-dose cycle every _____ weeks Other: _____ mg IV at week 0 and week _____ (leave blank if only one dose), then repeat cycle every _____ weeks		
Other Infusion medication (include dosing, frequency, and other pertinent information) _____			

Prescription Order

Pre-Medication: Premedication and anaphylaxis kit per AOM Infusion protocol unless otherwise stated.

Diphenhydramine PO or IV _____ mg, 15-30 minutes prior to each infusion

Acetaminophen PO _____ mg tablet, 15-30 minutes prior to each infusion

Methylprednisolone IV _____ mg, 20 minutes prior to each infusion

Other _____ PO or IV, Strength _____ Directions _____

Other _____ PO or IV, Strength _____ Directions _____

None

Nursing and Lab Orders

Infusion Nursing: RN to provide start of care assessment, place PIV or access CVAD, administer all prescribed medication per Rx, monitor for adverse effects, and teaching until independent with procedure if applicable.

Labs: Lab draw requests will undergo review by the AOM clinical team to assess for current capacity and clinical appropriateness. Please note that we are unable to provide STAT Lab draws or Lab draws on weekends, holidays, or evenings due to specimen stability, logistics, and other considerations.

Lab Order _____ Frequency of Labs: Once Every Infusion Every _____ weeks

Lab Order _____ Frequency of Labs: Once Every Infusion Every _____ weeks

Prescriber Information

Prescriber:

Office Contact Name:

Clinic/Practice Name:

Address:

City:

State:

Zip:

Phone:

Fax:

License #:

UPIN #:

NPI:

Prescriber Signature: _____ **Date:** _____

Substitutions permitted unless "No Substitution" is noted on this form.

By signing this form, you and your practice are consenting to receive communications from AOM Infusion. You authorize AOM Infusion to assist with prior authorization requests acting as your pharmacy provider in dealing with prescription and medical insurance organizations.

This form is not a valid order in the state of Arizona.

CONFIDENTIALITY NOTICE: The information contained in this communication and any additional attachments is confidential information or Protected Health Information (PHI) belonging to the sender and intended only for the use of the individual or entity named above. If you are not the intended recipient, or the employee or agent responsible for delivering this message to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this information in error, please notify AOM Infusion immediately at (800) 556-4246 to arrange for the return or destruction of the original document.

Fax completed form, insurance information, and clinical documentation to: **800-528-9860**. For any questions, please contact us at **800-746-9089** or visit our website **aominfusionrx.com**.